All In Biotech

Drug Trial Radar · NCT04519749

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Jan 2026

Study completion Jun 2030

Sponsor

Lead sponsor
4D Molecular TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.

Conditions

  • Fabry Disease

Interventions

  • 4D-310Biological

    4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse eventsTime frame: 1 year

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California at San Diego

    La Jolla, California

  • Emory University

    Atlanta, Georgia

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Lysosomal & Rare Disorders Research & Treatment Center, Inc

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.